Next Step For Pfizer After Nestle Sale: Get Drugs Approved, Sell Them.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      PFIZER Inc.; NESTLE Co. Inc.
    • Abstract:
      The article discusses the possible developments at Pfizer after the sale of its nutritional business to Nestle for 11.85 billion U.S. The author expects investors to look at another sale with Pfizer stating its exploration of options for its animal health business. According to the author, what is needed in running a successful drug company is the invention of new drugs, delivery of these drugs to the market, and then its sales. Tofacitinib will go before a panel of experts on May 9, 2012.